What is Modulo Bio?
Modulo Bio operates at the intersection of advanced biotechnology and neurological research. Based in San Diego, a global hub for life sciences, the company focuses on developing sophisticated methodologies to understand and treat conditions affecting the nervous system. By integrating cutting-edge scientific inquiry with a scalable business model, Modulo Bio aims to bridge the gap between laboratory discovery and clinical application. Its market position is defined by a commitment to addressing high-unmet-need areas within neurology, utilizing a data-driven approach to therapeutic development that distinguishes it from traditional pharmaceutical entities.
How much funding has Modulo Bio raised?
Modulo Bio has raised a total of $8M across 1 funding round:
Other Financing Round
$8M
Other Financing Round (2023): $8M with participation from Initialized Capital, Bioverge, and Builders VC
Key Investors in Modulo Bio
Initialized Capital
Initialized Capital is a venture capital firm dedicated to supporting seed stage founders across various sectors including enterprise SaaS, sustainability, health, hard tech, artificial intelligence, infrastructure, consumer, and crypto.
Bioverge
Bioverge is an investment platform that funds visionary entrepreneurs with the aim of transforming healthcare and bringing science fiction to life, focusing on the intersection of Health and Tech.
Builders VC
Builders VC is a venture capital firm focused on modernizing antiquated industries by investing in innovative technologies and solutions, with a specific interest in healthcare and complex system transformation.
What's next for Modulo Bio?
With the successful closure of this major strategic investment, Modulo Bio is poised to enter a period of accelerated growth and operational expansion. The company is expected to prioritize the advancement of its core research pipeline, potentially moving toward more rigorous clinical validation phases. Furthermore, the involvement of high-profile venture capital partners suggests a long-term strategy focused on commercial viability and the potential for future partnerships within the broader healthcare ecosystem. As Modulo Bio continues to navigate the complexities of the biotech industry, the focus will likely remain on achieving key technical milestones that demonstrate the efficacy and scalability of its nervous system-focused platform, ultimately aiming to deliver transformative outcomes for patients and stakeholders alike.
See full Modulo Bio company page
